Key facts
- It has raised $41.9M; the latest was Later Stage VC ($360K) in Jul 2024.
- Notable investors include KB Investment, Korea Development Bank, NH Investment & Securities, Magellan Technology Investment, Meritz Securities — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Wellmarker Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Wellmarker Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Wellmarker Bio
Developer of anticancer drugs designed to treat cancer patients with medical advancement. The company specializes in developing predictive biomarkers and first-in-class drugs through profound research know-how and a research Institute that comprises a target discovery department, drug discovery department, and medicinal chemistry department, enabling healthcare providers to cure their patients and improve their lives.
- Sector
- Healthcare
- HQ
- Hanam, South Korea
- Founded
- 2016
- Employees
- 7
- Website
- wmbio.co/
- Ownership
- Privately Held (backing)
Wellmarker Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Wellmarker Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Wellmarker Bio in its N-PORT filings yet. We sweep new filings monthly.